Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
0.5 - 2 μg/mL |
0.5 - 5 μg/mL |
0.5 - 5 μg/mL |
0.5 - 2 μg/mL |
Not tested in other applications.
Calculated MW
Product Note
This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF.
Form
Liquid
Buffer
PBS, 1% BSA, 50% Glycerol
Preservative
0.09% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
A peptide corresponding to BRAF V600E mutant
Purification
Protein A purified
From tissue culture supernatant
Conjugation
Unconjugated
RRID
AB_2887722
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
BRAF,BRAF1,BRaf protooncogene, serine/threonine kinase,Braf,NS7,RAFB1,B-Raf,B-Raf proto-oncogene, serine/threonine kinase
Cellular Localization
Nucleus,Cytoplasm,Cell membrane
Background
This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]
Database
Research Area